Advanced maternal age (AMA;> 35 year) is associated with a decline in both ovarian
reserve and oocyte competence. At present, no remedies are available to counteract the …

Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) play complementary roles
in follicle development and ovulation via a complex interaction in the hypothalamus, anterior …

With our increasing appreciation that simply maximizing oocyte yield for all patients is no
longer an appropriate stimulation strategy and that age alone cannot accurately predict …

Many strategies have been proposed to manage poor responder patients, however, a
consensus upon which is the most beneficial has not been yet reached. DuoStim is the most …

Despite the fact that in the last two decades an enormous number of papers on the topic of
poor ovarian response have been published in the literature, so far it has been impossible to …

Despite the considerate progress to which assisted reproduction technology (ART) has been
subject since 1978, some issues remain unresolved. Notably, the clinical management of …

Luteinizing hormone (LH) in synergy with follicle stimulating hormone (FSH) stimulates
normal follicular growth and ovulation. FSH is frequently used in assisted reproductive …

STUDY QUESTION How does the efficacy and safety of a fixed-ratio combination of
recombinant human FSH plus recombinant human LH (follitropin alfa plus lutropin alfa; r …

Background The potential benefit of adding recombinant human luteinizing hormone (r-hLH)
to recombinant human follicle-stimulating hormone (r-hFSH) during ovarian stimulation is a …

Background One of the various ovarian stimulation regimens used for in‐vitro fertilisation
(IVF) or intracytoplasmic sperm injection (ICSI) cycles is the use of recombinant follicle …